ADMIT

admit-therapeutics.com LinkedIn

ADmit Therapeutics has a CE-marked test that predicts whether mild cognitive impairment will progress to Alzheimer's, built on a mitochondrial DNA biomarker.

Industry

Healthtech

Company size

11-50

In Barcelona

1-10

Founded

2017

AI highlights Public evidence, checked Sep 2026

Product A disruptive CE-marked in vitro prognostic solution based on the first mitochondrial DNA epigenetic biomarker for Alzheimer's dementia, employing Next Generation Sequencing and Machine Learning techniques . Names the technique "machine learning", on its own site Sep 2026 ↗

At the campus

No sessions with ADMIT are planned yet.

Want to hear from them? Tell us what you would like them to talk about and we will ask.

I want to hear from them